Stay updated with breaking news from End Results Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial ELREXFIO is an off-the-shelf ,...
08.12.2023 - Pfizer Inc. (NYSE:PFE) today announced the European Commission (EC) has granted conditional marketing authorization for ELREXFIO (elranatamab). ELREFXIO is a targeted immunotherapy for the treatment of adult patients with relapsed and refractory ...
AstraZeneca's Truqap approved in the US for HR-positive breast cancer
Most patients with cancer may not be discussing the cost of care with their clinicians, according to recent research.
As a result of the Affordable Care Act’s Medicaid expansion, positive trends are becoming apparent regarding mortality rates for patients with cancer living in the states that have adopted Medicaid expansion.